gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Article

Send article

Transperineal Permanent Seed Implantation of “Low Risk” Prostate Cancer: 5 Years Experiences in 112 Patients

Meeting Abstract

Search Medline for

  • corresponding author presenting/speaker Thomas Block - Urologie und Medizinphysik, Vaterstetten, Deutschland
  • F. Zimmermann - Klinik für Strahlentherapie und Radioonkologie, TU Münchenl
  • H. Czempiel - Urologie und Medizinphysik, Vaterstetten

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPE325

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk435.shtml

Published: March 20, 2006

© 2006 Block et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Purpose: Evaluation of effectiveness of transperineal permanent seedimplantation (TPSI) in 112 patients with “low risk” prostate cancer.

Patients/Methods: From 04/1999 – 05/2002 112 patients underwent a mono TPSI using pre-, online and CT-plan procedures. Patients were monitored during the first year in 3 month intervals and from the 2.-5. year six monthly. Criteria for tumor relapse were 3 consecutive PSA rises (ASTRO criteria).

Results: 4 patients were lost to follow up, 108 patients were eligible. After a median follow up of 48.2 (37.0-76.7) months 102 patients had a biochemical free survival (bNED). In 6 patients (5.6%) a PSA relapse occurred (local recurrence: 3, systemic disease: 3). In the bNED-patients PSA values were <0.2 ng/ml in 85/102 (81,7%), <0.5 ng/ml in 99/102 (97,1%) and <1.0 ng/ml in 100/102 (98.0%) patients, respectively. 2/102 (2.0%) of patients have stable PSA values <1.5 ng/ml.

Conclusions: Crucial selection of patients and high quality assurance lead to excellent results after TPSI.